2019 ESC Guidelines for Supraventricular Tachycardia

Summary & Key Changes

The 2019 ESC Guidelines provide comprehensive evidence-based recommendations for the management of supraventricular tachycardia in adults and children. This update emphasizes a diagnostic-guided approach using 12-lead ECG during tachycardia, electrophysiology study, and response to adenosine. Key management decisions balance immediate symptom relief with long-term prevention through catheter ablation versus antiarrhythmic therapy.

Key Changes from 2003 Guidelines

Enhanced diagnostic algorithm emphasizing adenosine response patterns and ECG criteria
Upgraded catheter ablation to first-line therapy for symptomatic SVT (Class I)
New recommendations for antiarrhythmic drug selection based on structural heart disease
Specific guidance for pre-excited atrial fibrillation and risk stratification in asymptomatic pre-excitation
Updated recommendations for SVT management in pregnancy and athletes
Expanded coverage of SVT in congenital heart disease and tachycardiomyopathy

SVT Classification & Mechanisms

SVTs are organized into three major categories based on mechanism and anatomical substrate, each with distinct diagnostic features and therapeutic implications.

Category	Subtypes	Mechanism	Key Features
Sinus Node Arrhythmias	Inappropriate sinus tachycardia (IST); Sinus node reentrant tachycardia (SNRT)	Enhanced automaticity or microreentry in SA node	Gradual onset/offset; sinus P wave morphology
Atrial Arrhythmias	Focal atrial tachycardia; Macro-reentrant atrial tachycardia; Atrial flutter	Focal automaticity, triggered activity, or large reentry circuits	AV nodal conduction variable; distinct P wave morphology
Atrioventricular Arrhythmias	AVNRT; AVRT (orthodromic/antidromic); Junctional tachycardias; Permanent junctional reciprocating tachycardia (PJRT)	Reentry involving AV node and accessory pathway; nodal automaticity	RP interval variable; narrow QRS typically; depends on conduction pathway

Diagnostic Approach

12-Lead ECG During Tachycardia — Gold Standard

The ECG during tachycardia is the most important diagnostic tool. Key parameters include RP interval (onset of R wave to P wave), PP interval, AV block characteristics, and concordance patterns.

Figure 1: Differential diagnosis of narrow QRS tachycardia flow diagram

Adenosine Response, RP Interval & AV Block Characteristics
Initial response to adenosine distinguishes AVNRT/AVRT (abrupt termination with 1:1 AV block) from atrial tachycardia/flutter (AV block with continued atrial activity). RP interval classifies as short RP (RP < PR, typical AVNRT/orthodromic AVRT), long RP (RP > PR, atypical AVNRT/AVRT), or RP = 0 (sinus tachycardia). AV block response confirms reentrant mechanism and guides diagnosis.

Response to Adenosine

AVNRT/AVRT: Abrupt termination with 1:1 AV block (typical response)
Atrial tachycardia/flutter: AV block continuation of atrial activity (or acceleration with antidromic AVRT)
Sinus tachycardia: Gradual slowing without abrupt termination
Pre-excitation with AF: May precipitate VF if accessory pathway has short refractory period — avoid adenosine

Electrophysiology Study (EPS)

Indicated when ECG diagnosis is uncertain, ablation is planned, or risk stratification needed (especially in asymptomatic pre-excitation).

AVNRT: Dual AV nodal pathways; echo beat; AV nodal echo beat
AVRT: Earliest atrial activation at accessory pathway site; manifest or concealed pre-excitation
Atrial tachycardia: Focal activation pattern; response to pacing maneuvers
Atrial flutter: Counterclockwise or clockwise activation around CTI

Acute Management Algorithms

Narrow QRS Tachycardia (Diagnosis Unknown)

Initial therapy focuses on vagal maneuvers and adenosine. Synchronized cardioversion for hemodynamic instability or failed adenosine.

Figure 4: Acute therapy of narrow QRS tachycardia management algorithm

Hemodynamically Stable: Sequential Approach
1) Vagal maneuvers (ice face reflex, Valsalva) as first-line.
2) IV adenosine 6-12mg if vagal maneuvers fail (preferred agent for hemodynamically stable narrow QRS SVT).
3) IV verapamil/diltiazem or beta-blocker if adenosine contraindicated or ineffective.
4) Synchronized cardioversion if all medical measures fail.

Hemodynamically Unstable
Proceed directly to synchronized cardioversion without delay.

Wide QRS Tachycardia (Diagnosis Unknown)

Assume ventricular tachycardia until proven otherwise. Adenosine has limited role; primary therapy is synchronized cardioversion or IV antiarrhythmics.

Figure 5: Acute therapy of wide QRS tachycardia management algorithm

Assume VT Until Proven Otherwise
Adenosine has limited role in wide QRS tachycardia of unknown origin.

Hemodynamically Stable
IV procainamide or ibutilide (Class IC antiarrhythmics) preferred for wide QRS tachycardia management if stable.

Hemodynamically Unstable
Synchronized cardioversion without delay.

Atrioventricular Nodal Reentrant Tachycardia (AVNRT)

The most common SVT in adults (60% of all SVTs). Due to dual AV nodal pathways; slow and fast pathways create reentry circuit within or near the AV node.

Mechanism & ECG Features

Figure 13: AVNRT mechanism diagram showing dual pathways and reentry circuit

Typical AVNRT (Slow-Fast, 90%)
Anterograde conduction over slow pathway, retrograde via fast pathway. Results in short RP interval with P wave buried in or immediately after QRS complex.

Atypical AVNRT (Fast-Slow)
Anterograde conduction over fast pathway, retrograde via slow pathway. Results in long RP interval (RP > PR) with P wave appearing late in diastole, may mimic AVRT.

Key Feature
Both variants require intact dual AV nodal pathways; AV block terminates tachycardia confirming dual pathway involvement.

ECG Diagnostic Criteria

Typical (Slow-Fast, 90% of AVNRT): Short RP tachycardia; P wave at or after QRS; retrograde P often buried in or immediately after QRS
Atypical (Fast-Slow): Long RP tachycardia (RP > PR); P wave appears late in diastole, may mimic AVRT
AV block terminates tachycardia: Confirms participation of both slow and fast pathways

Acute Therapy

Figure 14: Acute therapy of AVNRT management algorithm

Hemodynamically Stable
1) Vagal maneuvers as first-line.
2) IV adenosine 6-12mg (preferred agent; causes 1:1 AV block terminating tachycardia).
3) IV verapamil or diltiazem if adenosine contraindicated.
4) IV beta-blocker if calcium channel blocker contraindicated.

Hemodynamically Unstable
Synchronized cardioversion.

Chronic Therapy & Ablation Indications

Figure 15: Chronic therapy of AVNRT management algorithm

Symptomatic AVNRT — First-Line Ablation (Class I)
Catheter ablation is Class I recommendation for symptomatic patients due to 95-99% success rate, low recurrence (2-5%), and excellent long-term cure rate.

Medical Management (If Ablation Deferred)
Beta-blockers (e.g., metoprolol, atenolol) or calcium channel blockers (verapamil, diltiazem) for symptomatic episodes. Consider antiarrhythmic drugs (flecainide, sotalol) if beta/CCB ineffective, with dose titration based on symptom burden.

Asymptomatic AVNRT
No treatment required; reassure patient.

Catheter Ablation (Preferred First-Line for Symptomatic AVNRT)

Success rate: 95–99%
Target: Slow pathway ablation or fast pathway (if dual AV nodal conduction preserved)
Risk of AV block: <1% with slow pathway; higher with fast pathway
Risk of accelerated junctional rhythm: Common during slow pathway ablation, usually benign
Recurrence: 2–5% (due to slow pathway regeneration)

Atrioventricular Reentrant Tachycardia & Wolff-Parkinson-White Syndrome

AVRT accounts for 30–40% of SVTs. Requires an accessory pathway (AP) with ability to conduct in retrograde direction (AVRT) or antegrade direction (pre-excitation).

Mechanism & Accessory Pathway Localization

Figure 16: St George's algorithm for accessory pathway localization

Delta Wave Axis & QRS Morphology Analysis
Examines direction of maximum delta wave (axis deviation) and QRS polarity across precordial leads to predict accessory pathway location.

Regional Localization
Left lateral, right lateral, posteroseptal, anteroseptal, or right free wall based on concordance patterns and lead-specific morphology criteria.

Clinical Use
Guides catheter placement strategy during electrophysiology study and ablation for efficient AP site identification and elimination.

AVRT — Orthodromic & Antidromic

Figure 18: AVRT mechanism showing orthodromic and antidromic pathways

Orthodromic AVRT (90% of AVRT)
Anterograde conduction via AV node (narrow QRS) and retrograde conduction via accessory pathway. Presents as narrow QRS tachycardia; may be difficult to distinguish from AVNRT without EPS.

Antidromic AVRT (10% of AVRT)
Anterograde conduction via accessory pathway and retrograde via AV node. Presents as wide QRS tachycardia with continuously negative QRS and delta wave morphology throughout tachycardia (distinguishes from VT).

Clinical Significance
Both require intact accessory pathway with appropriate refractory periods; AV block terminates orthodromic AVRT but not antidromic AVRT.

Acute AVRT Management

Figure 19: Acute therapy of AVRT management algorithm

Orthodromic AVRT (Narrow QRS) — Hemodynamically Stable
1) Vagal maneuvers.
2) IV adenosine 6-12mg (preferred; blocks AV node, terminates anterograde limb).
3) IV verapamil/diltiazem or beta-blocker if adenosine contraindicated.

Antidromic AVRT (Wide QRS) or Rapid AP Conduction
AVOID adenosine and AV nodal blockers (block AV node, forcing more conduction down rapid AP, risking VF). Use IV procainamide or ibutilide instead.

Hemodynamically Unstable
Synchronized cardioversion.

WPW Syndrome Risk Stratification

Asymptomatic Pre-excitation — EPS Risk Stratification Required

High Risk (Recommend ablation): AP effective refractory period <250 ms; shortest RR interval during AF <250 ms
Intermediate Risk: AP refractory period 250–300 ms; clinical context guides decision
Low Risk (No ablation required): AP refractory period >300 ms; minimal VF risk
Pre-excited AF management: Avoid AV nodal blockers (adenosine, beta-blockers, CCBs); use IV procainamide or ibutilide

Catheter Ablation for AVRT

Success rate: 95–99%
Target: Accessory pathway (identified by earliest retrograde or antegrade activation)
Approach: Transseptal catheterization for left-sided APs; right atrial for right-sided APs
Risk of AV block: <1% (mainly para-Hisian APs); no increased AV nodal conduction delay
Recurrence: 2–5%

Focal Atrial Tachycardia

Accounts for 5–15% of SVTs. Arises from a single focus in atrium via automaticity, triggered activity, or microreentry. Variable AV conduction distinguishes from AVNRT/AVRT.

Diagnostic Features

ECG: Distinct P wave morphology; variable AV conduction; AV block may unmask tachycardia without termination
Adenosine response: Slowing with AV block, continuation of atrial activity
Onset/offset: Often gradual (unlike paroxysmal AVNRT/AVRT)
EPS: Focal activation pattern; pacing maneuvers identify mechanism

Treatment Options

Acute & Chronic Therapy

Acute: IV beta-blocker, CCB, or digoxin to slow AV conduction; adenosine less effective
Chronic: Beta-blockers or CCBs (first-line); antiarrhythmics if inadequate rate control
Catheter ablation: Consider for incessant tachycardia, young patients, or drug intolerance
Success rate of ablation: 80–90%; recurrence 5–10%
Tachycardiomyopathy risk: If uncontrolled rate >120 bpm for months → may develop dilated cardiomyopathy

Atrial Flutter & Macro-Reentrant Atrial Tachycardia

Mechanical reentry around anatomical structures (typical atrial flutter) or areas of scar/ablation (atypical/left atrial flutter). Regular atrial rate 240–320 bpm with fixed AV conduction (often 2:1).

Typical Atrial Flutter (CTI-Dependent)

Counter-clockwise: Most common (90%); sawtooth flutter waves in inferior leads (II, III, aVF)
Clockwise: Less common; upright flutter waves in inferior leads
Circuit: Reentry around cavotricuspid isthmus (CTI) between IVC and tricuspid valve
AV conduction: Usually 2:1 (atrial rate 300 → ventricular rate 150)

Acute Management

Hemodynamically unstable: Synchronized DC cardioversion (100–200 J)
Stable: IV rate control (beta-blocker, CCB) followed by antiarrhythmics (flecainide, sotalol, amiodarone)
Pharmacological cardioversion: Ibutilide, flecainide, or amiodarone (20–50% success)
Warning: AV nodal blockers alone may paradoxically accelerate ventricular rate (via enhanced 1:1 conduction); always use AV nodal blocker + antiarrhythmic or pacing

Catheter Ablation (Class I for Typical Flutter)

Target: CTI ablation creating bidirectional block
Success rate: 95–99%
Recurrence: 2–5% (gap in ablation line)
Advantages: Avoids long-term antiarrhythmic therapy; very high success

Chronic Management & Anticoagulation

Rate control: Beta-blockers or diltiazem/verapamil (target HR <110 bpm)
Rhythm control: Antiarrhythmics (flecainide, sotalol, dofetilide, amiodarone) if symptoms persist
Stroke risk: Atrial flutter confers similar stroke risk as AF; consider anticoagulation per CHA₂DS₂-VA score

Catheter Ablation Indications & Success Rates

Catheter ablation is considered first-line therapy for most symptomatic SVTs due to high success rates, low complication rates, and avoidance of long-term antiarrhythmic therapy.

Arrhythmia	Class of Recommendation	Success Rate	Recurrence	Complications
AVNRT	Class I (symptomatic)	95–99%	2–5%	<1% AV block (slow pathway)
AVRT (orthodromic)	Class I (symptomatic)	95–99%	2–5%	<1% major complications; risk varies by AP location
Atrial Tachycardia (focal)	Class IIa (symptomatic/incessant)	80–90%	5–10%	<2% serious complications
Typical Atrial Flutter (CTI)	Class I (first-line)	95–99%	2–5%	<1% major complications
Atypical/Left Atrial Flutter	Class IIa	80–90%	10–15%	Esophageal/phrenic nerve injury risk; transseptal approach required

General Procedural Considerations

Anticoagulation: Uninterrupted oral anticoagulation during procedure (if indicated clinically); heparin bolus at start; protamine reversal post-procedure
Sedation: Moderate sedation or general anesthesia per institutional protocol
Mapping: 3D electroanatomical mapping recommended to identify earliest activation site
Ablation: Radiofrequency (RF) catheter standard; cryoablation alternative (lower success, lower complication rate in high-risk locations)
Follow-up: Holter/event monitor at 3 months post-ablation to assess for arrhythmia recurrence

Antiarrhythmic Drug Therapy

When catheter ablation is declined, contraindicated, or unsuccessful, antiarrhythmic drugs provide rate/rhythm control. Selection depends on structural heart disease, renal function, and drug interactions.

Drug Class / Agent	SVT Indication	Dose (Oral)	Adverse Effects & Interactions	Special Populations
Rate Control Agents (First-Line)
Beta-blockers (metoprolol, atenolol, bisoprolol)	AVNRT, AVRT, atrial tachycardia, AF	50–200 mg daily (metoprolol)	Bradycardia, fatigue, sexual dysfunction; caution in asthma/COPD	Avoid in acute decompensated HF; safe in pregnancy
Diltiazem (non-dihydropyridine CCB)	AVNRT, AVRT, atrial tachycardia, AF	120–360 mg daily (extended-release)	Constipation, ankle edema, AV nodal conduction delay; negative inotrope	Avoid in HFrEF; safe in pregnancy
Verapamil (non-dihydropyridine CCB)	AVNRT, AVRT, atrial tachycardia	120–360 mg daily (extended-release)	Constipation, headache, ankle edema; stronger negative inotrope than diltiazem	Avoid in HFrEF; safe in pregnancy; preferred over diltiazem in some guidelines
Rhythm Control Agents (Antiarrhythmics)
Flecainide (IC)	AVNRT, AVRT, atrial tachycardia, AF	100–200 mg daily (divided dose)	Proarrhythmia (especially in structural heart disease); blurred vision; QRS widening	Contraindicated in coronary artery disease, prior MI; avoid if LVEF <40%
Propafenone (IC, also IB-like)	AVNRT, AVRT, atrial tachycardia, AF	150–300 mg daily (divided dose)	Proarrhythmia; metallic taste; beta-blocker activity (bradycardia)	Contraindicated in coronary artery disease, structural heart disease; caution in HF
Sotalol (III + beta-blocker)	AVNRT, AVRT, atrial tachycardia, AF	80–160 mg twice daily	QT prolongation → Torsades de Pointes; renal clearance-dependent; bradycardia	Monitor QTc; avoid if Cr <40 mL/min; caution in HFrEF; safe in pregnancy
Dofetilide (III, pure)	AVNRT, AVRT, atrial tachycardia, AF	125–500 mcg twice daily (dose-adjusted per renal function)	QT prolongation → Torsades; requires baseline & periodic ECG monitoring; renal clearance-dependent	Must measure Cr & QTc; avoid if Cr <20 mL/min; caution in HF
Amiodarone (III + I, II, IV properties)	Recurrent SVT despite ablation; tachycardiomyopathy	200 mg daily (after loading 600 mg × 1 week)	Organ toxicity (thyroid, liver, lung, skin); photosensitivity; QT prolongation; drug interactions	Most effective but significant adverse effects; reserve for refractory SVT; safe in HF & CAD
Ivabradine (selective If inhibitor)	Rate control in chronotropic-incompetent patients	5–7.5 mg twice daily	Bradycardia (selective HR reduction); visual effects (phosphene)	Not first-line; avoid in SSS; safe in HF; no cardiac structure effect
Digoxin (rarely used)	Rate control in specific settings (atrial tachycardia/flutter with HF)	0.25–0.5 mg daily	Narrow therapeutic window; toxicity (arrhythmias, GI effects); drug interactions	Limited role; preferred agents are BBs/CCBs; monitor renal function & levels

Drug Selection by Clinical Scenario

No structural heart disease: Beta-blockers/CCBs first-line; flecainide/propafenone if inadequate
Coronary artery disease or prior MI: Beta-blockers/CCBs; amiodarone if needed; avoid flecainide/propafenone
HFrEF (LVEF <40%): Beta-blockers only; amiodarone if refractory; avoid flecainide/propafenone/verapamil/diltiazem
Hypertension with LVH: Beta-blockers/CCBs; sotalol alternative
Pregnancy: Beta-blockers, verapamil, digoxin (safe); amiodarone, sotalol, flecainide (reserved for refractory)
Renal impairment: Avoid or adjust sotalol, dofetilide; CCBs/beta-blockers generally safe

Special Populations & Scenarios

SVT in Pregnancy

Presentation: 50% of AVNRT episodes occur or worsen during pregnancy due to increased AV nodal conduction
Acute management: Vagal maneuvers first; IV adenosine safe (minimal placental transfer); synchronized cardioversion if unstable
Chronic therapy: Beta-blockers (metoprolol, labetalol preferred); verapamil safe; avoid flecainide/amiodarone (first-trimester teratogenicity)
Catheter ablation: Safe (especially second/third trimester); technique reduces long-term medication exposure
Monitoring: Fetal heart rate baseline & variability; maternal heart rate control

SVT in Athletes

Diagnostic workup: ECG, EPS, and structural imaging to exclude underlying disease
Sports participation: Depends on symptom severity, underlying substrate, and arrhythmia hemodynamics
AVNRT/AVRT: Generally low risk; ablation recommended if symptomatic during competition; asymptomatic pre-excitation requires risk stratification
Asymptomatic high-risk pre-excitation: EPS risk stratification (AP refractory period <250 ms → recommend ablation before competition)
Return to play: 2–4 weeks post-ablation depending on procedure complications

SVT in Congenital Heart Disease

Increased incidence: AVNRT/AVRT more common in Ebstein anomaly, L-TGA, heterotaxy
PJRT: Permanent junctional reciprocating tachycardia; incessant tachycardia leading to tachycardiomyopathy
Anatomical challenges: Complex atrial anatomy complicates catheter ablation; may require irrigated radiofrequency or cryoablation
Therapy: Antiarrhythmics (amiodarone, sotalol) often needed; ablation success lower than in structurally normal hearts
Device therapy: Pacemaker may be needed if ablation unsuccessful or recurrent

SVT-Induced Tachycardiomyopathy

Mechanism: Chronic rapid ventricular rate (typically >120 bpm × weeks to months) causes progressive systolic dysfunction
Most common causes: Incessant focal atrial tachycardia, rapid atrial flutter, PJRT
Recovery: LVEF improves significantly after arrhythmia termination (weeks to months)
Management: Aggressive rate control or ablation; acute diuretics/ACE-I for LV dysfunction
First-line ablation: Consider early ablation to prevent irreversible cardiac remodeling

Key Do's & Don'ts

DO — Management Principles

Class I Obtain 12-lead ECG during tachycardia whenever possible for diagnosis
Class I Use vagal maneuvers as first-line acute management (supine position, ice, Valsalva)
Class I IV adenosine is preferred acute agent for hemodynamically stable narrow QRS SVT
Class I Offer catheter ablation as first-line therapy for symptomatic AVNRT and AVRT
Class I Perform EPS and ablation for typical atrial flutter (CTI ablation)
Class I Anticoagulation in atrial flutter per CHA₂DS₂-VA score (similar to AF)
Class I Consider antiarrhythmic prophylaxis in frequent SVT episodes between ablation attempts

DON'T — Pitfalls to Avoid

Class III Do NOT use adenosine for pre-excited atrial fibrillation (risk of VF if short AP refractory period)
Class III Do NOT use AV nodal blockers alone for rate control in atrial flutter without antiarrhythmic (paradoxical acceleration via 1:1 conduction)
Class III Do NOT use IC antiarrhythmics (flecainide, propafenone) in CAD or structural heart disease without EPS guidance
Class III Do NOT give IV verapamil/diltiazem with concurrent IV beta-blocker (risk of profound bradycardia/AV block)
Class III Do NOT recommend ablation for asymptomatic SVT (low risk, no symptoms to prevent)
Class III Do NOT delay ablation in SVT-induced tachycardiomyopathy (early intervention prevents irreversible remodeling)
Class III Do NOT use adenosine in patients with acute coronary syndrome (ACS) without careful risk-benefit assessment

Related Calculators & Tools

Integrated clinical tools to support SVT diagnosis, risk stratification, and treatment decisions.